HC Wainwright Issues Pessimistic Outlook for NRXP Earnings

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) – Stock analysts at HC Wainwright reduced their Q3 2026 earnings estimates for NRx Pharmaceuticals in a research note issued on Tuesday, March 3rd. HC Wainwright analyst P. Trucchio now forecasts that the company will earn $0.03 per share for the quarter, down from their previous estimate of $0.04. HC Wainwright currently has a “Buy” rating and a $45.00 price target on the stock. The consensus estimate for NRx Pharmaceuticals’ current full-year earnings is ($1.75) per share. HC Wainwright also issued estimates for NRx Pharmaceuticals’ FY2030 earnings at $6.15 EPS.

A number of other equities research analysts also recently weighed in on NRXP. Weiss Ratings reiterated a “sell (e+)” rating on shares of NRx Pharmaceuticals in a research report on Monday, December 29th. BTIG Research restated a “buy” rating and set a $25.00 price objective on shares of NRx Pharmaceuticals in a research note on Wednesday, February 18th. Zacks Research upgraded NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday. D. Boral Capital reissued a “buy” rating and set a $34.00 target price on shares of NRx Pharmaceuticals in a report on Tuesday, February 17th. Finally, Wall Street Zen raised NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, November 23rd. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, NRx Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $38.00.

NRx Pharmaceuticals Stock Up 3.9%

NASDAQ NRXP opened at $1.87 on Wednesday. The firm has a 50-day moving average price of $2.11 and a two-hundred day moving average price of $2.51. NRx Pharmaceuticals has a 12-month low of $1.58 and a 12-month high of $3.84. The company has a market capitalization of $59.60 million, a P/E ratio of -0.80 and a beta of 1.97.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in NRXP. Ethos Financial Group LLC bought a new stake in shares of NRx Pharmaceuticals during the 3rd quarter valued at approximately $39,000. Sjbenen Advisory LLC acquired a new stake in NRx Pharmaceuticals in the fourth quarter valued at approximately $41,000. One Wealth Management Investment & Advisory Services LLC grew its stake in shares of NRx Pharmaceuticals by 86.1% during the third quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock worth $92,000 after buying an additional 12,950 shares during the last quarter. Global Retirement Partners LLC acquired a new position in shares of NRx Pharmaceuticals during the fourth quarter worth $107,000. Finally, Two Sigma Investments LP increased its holdings in shares of NRx Pharmaceuticals by 66.4% during the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after buying an additional 20,880 shares in the last quarter. Institutional investors own 4.27% of the company’s stock.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.